Vireo Growth (VREOF) Other Accumulated Expenses (2020 - 2025)

Vireo Growth (VREOF) posted Other Accumulated Expenses of $77128.0 for Q4 2025, down 83.93% sequentially from $479959.0 in Q3 2025.

Vireo Growth (VREOF) Other Accumulated Expenses (2020 - 2025) Analysis & Trends

Vireo Growth has reported Other Accumulated Expenses for 3 years, with the latest figure at $77128.0 in Q4 2025.

Quarterly Other Accumulated Expenses changed N/A year-over-year to $77128.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $77128.0 (changed N/A YoY) and the FY2025 annual result came in at $77128.0, changed N/A from the prior year.
Other Accumulated Expenses declined to $77128.0 in Q4 2025 per VREOF's latest filing, from $479959.0 in the prior quarter.
Over five years, Other Accumulated Expenses peaked at $720601.0 in Q3 2021 and troughed at $77128.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	43.89 Bn	42.93 Bn	-
2	Teva Pharmaceutical Industries	42.98 Bn	39.33 Bn	2.15 Bn
3	Zoetis	31.54 Bn	29.86 Bn	1.05 Bn
4	Takeda Pharmaceutical	28.61 Bn	22.81 Bn	5.10 Bn
5	United Therapeutics	22.15 Bn	19.48 Bn	683.80 Mn
6	Viatris	18.75 Bn	17.86 Bn	1.46 Bn
7	Neurocrine Biosciences	15.56 Bn	15.17 Bn	935.80 Mn
8	Elanco Animal Health	11.74 Bn	11.21 Bn	798.00 Mn
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-
10	Vireo Growth	491.44 Mn	349.14 Mn	95.30 Mn

Download Data